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ABSTRACT Selection is usually considered to be the
dominant force controlling viral variation; the large popula-
tion sizes suggest that deterministic population genetic models
are appropriate. To investigate their validity for HIV, samples
of env gene sequences were tested for departure from neutral-
ity because of mutation–selection balance. None of the sam-
ples departed significantly when tested as nucleotide se-
quences. At the amino acid level, significantly elevated diver-
sity was detected in two samples within, but not outside, the
V3 loop. The effective population number has been estimated
(using a phylogenetic method) to be close to 103. Estimates
from nucleotide diversity are about 2-fold lower. The low value
of the effective population number might arise from high
variability in progeny number between infected cells, from the
expansion in population number from a small inoculum as the
virus is transmitted between hosts, or from variable selection
at linked sites. These results suggest that the population
genetics of HIV are best described by stochastic models.
The precise impact of selection in determining the level and
pattern of variation in the env gene of HIV-1 remains unclear
despite extensive studies of sequence variation (reviewed in
refs. 1–3). This gene encodes known targets for cytotoxic T
lymphocytes and neutralizing antibodies (4–6), and it is a
major determinant of cell tropism (7, 8), but there is only
indirect evidence (based on a lower frequency of synonymous
nucleotide substitutions than those that result in a change of
the amino acid sequence in the V3 loop) that variation in env
is maintained by selection for antigenic diversity (9, 10). To
date, there has been no formal attempt to test population data
of env sequences for departures from the expectations of
selective neutrality even though nonselective explanations for
env gene diversity have been proposed (11). In most theoretical
discussions, it has been assumed that selection and mutation
are the only important forces affecting viral variability; the
evolution of the virus has been treated deterministically, and
the population size (N) in an infected individual has been
considered to be infinite (12, 13).
Although the population number of HIV is indeed very
large (14, 15), data on the genetic variability of HIV-1 within
an infected patient reveal features that are not explained by a
deterministic model. For example, despite the consistent rep-
licative advantage enjoyed by genomes bearing alleles confer-
ring resistance to zidovudine, the outcome in terms of the rate
at which such alleles become fixed is unpredictable. In a
minority of patients, the methionine3leucine substitution at
codon 41 in the reverse transcriptase domain of the pol gene
[which confers the highest levels of zidovudine resistance (16)]
is never observed (17, 18). Such unpredictability is not ex-
pected in deterministic models; they are generally not consid-
ered to be biologically realistic because of their failure to allow
for sampling effects (19). In contrast, stochastic, finite popu-
lation models recognize the importance of sampling in evolu-
tion. They also allow for a class of selectively neutral mutations
whose fate is determined entirely by random genetic drift. The
majority of synonymous nucleotide substitutions are usually
considered to belong to this class whereas it has been suggested
under a deterministic model that the level of synonymous
variation in HIV is determined by a balance between the
forward mutation rate and the rate of removal by purifying
selection (mutation–selection balance) (13).
To assess the appropriateness of deterministic models for
HIV populations, I have tested whether the pattern of varia-
tion in HIV-1 env sequences departs significantly from neu-
trality. The test applied can detect departures due tomutation–
selection balance and those due to selection for antigenic
diversity (20). No significant departure was observed overall at
the level of the nucleotide sequences; this allowed estimation
of the effective population number of HIV-1 within a patient,
which was found to be close to 103, about five orders of
magnitude lower than the census size for this patient.
MATERIALS AND METHODS
The data analyzed were obtained from five serial, postsero-
conversion plasma samples from an HIV-1-infected hemophil-
iac at '1-year intervals (years 3–7, inclusive) that were sub-
jected to limiting dilution-nested PCR after reverse transcrip-
tion of viral env sequences and were manually sequenced (9).
A phylogenetic analysis of the sequence data has been pub-
lished (21). A total of 77 sequences of the V3 region, 231 bp
long, were obtained; the overall level of variation was similar
to that observed in other studies (22, 23). Only plasma viral
sequences were included to ensure that the sample represented
the recently replicated viral population; it has been shown that
the proviral population in peripheral blood is heterogeneous,
containing both recently replicated and older variants (9).
During this period, the patient had a declining CD41 cell count
but was clinically asymptomatic. Clinical details have been
published elsewhere (9). Estimates of plasma viral load, ob-
tained in the course of the sequencing studies, ranged from
2.8 3 104 copiesyml (year 3) to 5.8 3 103 copiesyml in year 7
(L.Q. Zhang, unpublished data), suggesting an overall viral
population of the order of 108 during the study period. A
second data set of 81 amino acid sequences of the V1yV2
region of env (from four individual splenic white pulps from a
single patient) published by Cheynier et al. was also analyzed
(11).
Estimates of u (2Nem) were obtained using the program
FLUCTUATE, a development of the COALESCE program de-
scribed by Kuhner et al. (24). This was obtained from the the
LAMARC package distributed by M. Kuhner and J. Felsenstein
(Department of Genetics, University of Washington, Seattle).
It was compiled on a Sun Sparcstation Model 10 (Sun Micro-
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systems, Mountain View, CA) using the GNU C compiler with
an input tree obtained by the unweighted pair group mean
method. A constant population size was assumed, reflecting
the lack of substantial change in viral load during the study
period.
RESULTS
The numbers of variable sites and mean pairwise divergence
for each of the five samples obtained from the V3 region, along
with the value obtained for the test statistic D (20), are
presented (Table 1). The data were analyzed separately as
nucleotide, amino acid, and synonymous nucleotide sites (es-
timated by an unweighted pathway method). For no sample
was the pattern of sequence variation significantly different
from that expected under neutrality. Analyzed as amino acid
sequences, two of the five samples (years 4 and 6) showed a
higher value ofD that approached significance, suggesting that
selection may be acting on the amino acid sequence without
significantly affecting the overall pattern of variation at the
nucleotide level.
In view of the prior suggestion that the V3 loop itself is the
target of selection (3, 10, 25), the test was repeated using the
same samples but considering separately the 35-codon se-
quence of the loop and the 42-codon sequence flanking it. The
number of variable sites and mean number of pairwise differ-
ences are given in Table 2, again for both nucleotide and amino
acid sequences as well as synonymous sites. For the V3 loop,
one sample (year 6) showed a significant departure from the
expectations of the neutral model on nucleotide sequence data
(P , 0.05), and two samples (years 4 and 6) departed highly
significantly when amino acid sequences were considered (P,
0.001), all due to relatively high pairwise divergence (K) for the
number of variable sites. In contrast, no samples showed any
departure from neutrality in the flanking regions either as
nucleotide or as amino acid sequences. For no sample did the
value of D for synonymous nucleotide variation depart signif-
icantly from that expected under neutrality.
The tests on V3 region sequences did not support the
proposal that mutation–selection balance (which would be
detected as a negative value of the test statistic D) determines
the level of variation. To determine the generality of this result,
the same test was applied to a data set obtained by Cheynier
et al. (11) of sequences of the V1yV2 region of env amplified
from individual white pulps from the same spleen. This study
found substantial differences between white pulps in the
proviral populations present. Because of this heterogeneity,
the individual subpopulations were tested separately for fit to
a neutral model. One (LD6) out of the four tests showed a
highly significant departure from neutrality (Table 3), which
was in the direction predicted for mutation–selection balance,
with relatively low diversity (Kaa) for the number of variable
sites (Saa). The other three tests did not approach significance.
These results, taken together, provide evidence that selec-
tion can be detected in HIV-1 env gene sequences, but its
effects are not detectable at the nucleotide level except when
the V3 loop is considered separately. I have therefore esti-
mated 2Nem (u) using the maximum likelihood-based method
of Kuhner et al. (24) from the V3 sequences obtained in each
of the five plasma samples from patient p82 (Table 4). A recent
analysis of HIV-1 mutation rates found that the in vivo point
mutation rate was 2.4 3 1025 (26). From these two figures,
estimates of Ne can be obtained that range from 1.0 to 2.1 3
103 (Table 4). Also in Table 4, the mean nucleotide diversity,
expected to be equal to 2Nem, is presented for each sample
(3.2–5.6%). From these, Ne would be estimated to range from
5.1 3 102 to 1.1 3 103.
DISCUSSION
The analysis of nucleotide sequences from the V3 region of the
env gene revealed no significant departures from neutrality.
The test applied was designed to detect the effect of mutation–
Table 1. Parameters of genetic variability and a test for neutrality in sequences of the V3 region (231 bp) in five samples of plasma viral
RNA from an infected hemophiliac
Sample, year n Snuc Knuc Dnuc Saa Kaa Daa Ssyn Ksyn Dsyn
3 15 25 7.37 20.172 19 6.47 0.438 3 1.3 1.22
4 11 21 7.89 0.457 13 6.02 1.560 4 0.87 21.329
5 23 25 6.27 20.279 15 4.43 0.321 5 0.86 21.071
6 15 33 12.31 0.901 20 8.70 1.697 6 1.7 20.276
7 13 39 10.12 20.865 20 6.51 0.043 10 2.03 21.478
n, number of sequences; Snuc, number of variable nucleotide sites; Saa, number of variable amino acid sites; Ssyn, number of variable synonymous
nucleotide sites;Knuc, mean number of pairwise differences between nucleotide sequences;Kaa, mean number of pairwise differences between amino
acid sequences; Ksyn, mean number of pairwise differences at synonymous nucleotide sites; Dnuc, value of the test statistic for goodness-of-fit to
a neutral model (20) (nucleotide sequences); Daa, value of the test statistic for goodness-of-fit to a neutral model (amino acid sequences); Dsyn,
value of the test statistic for goodness-of-fit to a neutral model (20) (synonymous nucleotide sites).
Table 2. Genetic variability and departures from neutrality in two components of the V3 region
Sample, year n Snuc Knuc Dnuc Saa Kaa Daa Ssyn Ksyn Dsyn d, %
V3 loop alone, 105 bp
3 15 10 3.07 20.007 6 2.17 0.616 1 0.13 21.182 2.8
4 11 13 5.2 0.751 7 3.73 2.275† 3 0.55 21.585 5.0
5 23 13 3.46 20.062 8 2.52 0.528 2 0.25 21.202 3.3
6 15 18 8.25 1.991* 11 5.47 2.378† 3 1.07 0.475 7.9
7 13 21 5.68 20.690 11 3.21 20.382 5 1.26 20.777 5.2
V3 flanking regions, 126 bp
3 15 15 4.40 20.184 13 4.30 0.297 1 0.53 1.481 3.5
4 11 8 2.69 20.063 6 2.29 0.467 2 0.76 0.346 2.1
5 23 12 2.83 20.044 7 1.91 0.022 4 1.06 20.746 2.2
6 15 15 4.07 20.470 9 3.23 0.626 4 1.14 20.235 3.2
7 13 18 4.69 20.812 9 3.31 0.553 7 1.95 20.514 3.7
Symbols as for Table 1 except: d, mean of the pairwise nucleotide distances for each sample.
*P , 0.05; †P , 0.001.
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selection balance, which has been invoked to explain under a
deterministic model the low level of synonymous nucleotide
variation observed in HIV-1 sequence data (13). The failure to
detect any evidence of mutation–selection balance in nucleo-
tide sequences raises questions about the appropriateness of
such models.
When the sequences of the 35-amino acid V3 loop and its
f lanking regions were considered separately, the flanking
sequences again showed no departure from neutrality when
considered at the nucleotide or amino acid level. Sequences of
the V3 loop itself departed significantly in two samples (years
4 and 6; Table 2), revealing a greater diversity than expected
for the number of variable sites. The sequences present in those
samples (21) show variation that includes a charge difference
at amino acid site 11 in the V3 loop, known to be associated
with differences in cell tropism (27–29). This supports the view
that selection for differences in cell tropism can have a
dominant effect on the viral population in some samples. In an
earlier analysis of these data, the turnover of amino acid
variants was described in these samples using a phylogenetic
approach. The two sets of results suggest that strong selective
forces act at the amino acid level in these sequences but that
these forces are transient or stochastic in nature. Such ‘‘ran-
dom environment’’ effects (30) would be expected to expose
linked nucleotide variation to strongly stochastic influences,
which could have a substantial impact on nucleotide sequence
variation in this gene.
The method used here to evaluate departures from selective
neutrality is based on the infinite sites model. It has been
reported that the confidence intervals for the test statistic may
be affected by variation in substitution rates over sites (31),
resulting in a shift to more positive values of D even under
neutrality. This would lead to type 1 errors with respect to
positive values and type 2 errors with respect to negative values
of D and imply that even the two significant departures in the
V3 loop data set (Table 2) might not be real whereas the
significance of the large negative value observed in the V1yV2
data (Table 3) would be increased. With the results obtained,
there remains no evidence that mutation–selection balance has
a significant effect on nucleotide variation in these sequences.
Given that, it is desirable to identify the magnitude of the
stochastic influences on the nucleotide sequences, and this is
conventionally expressed as the effective population number
(Ne). The effective population number estimates from these
data are several orders of magnitude lower than the census size
(Table 4). Although variation in substitution rates over sites
also can cause errors in the estimation of u, these are unlikely
to be greater than 2- or 3-fold (24, 32).
The census size for the viral population in this patient was
estimated to be '108, and estimates for other patients have
ranged even higher (14, 15). The difference between Ne and N
is so large that several factors probably contribute toward it.
The titers of infectious viruses have been shown to be much
lower than the titers of viral particles (33, 34), and a significant
proportion of newly replicated viral genomes are expected to
carry an inactivating mutation that will prevent their replica-
tion. In addition, it is possible that clonal amplification of
infected T cell populations (11) could increase the variance of
progeny number and further reduceNe. Selection at other sites
in the genome (‘‘background’’ natural selection) has been
shown to have a significant effect on Ne (35). However, the
scale of the effect, with parameter values appropriate for HIV,
is likely to be less than an order of magnitude. In addition, HIV
infections are initiated from a small inoculum (36, 37) and
increase very rapidly to '1010 in the first stages of infection
(38), so a considerable reduction in Ne would be expected to
be due to this expansion. All of these factors could act together
with fluctuating selective forces to generate stochasticity in the
evolution of viral sequences.
The low estimate of the effective population number of HIV
implies that chance effects will have a significant impact on the
evolution of the population, especially for lower values of s. We
may conclude that the evolution of HIV is best described by
finite population models (39). This conclusion may explain, for
example, the persistence of zidovadine resistance-associated
mutations within a population after therapy has been discon-
tinued (40) or on transmission to a drug-naive patient (41, 42)
although s for the resistant variants has been estimated to be
over 10% in the absence of drug.† This result is very different
from the in vivo estimate of 1% obtained by Goudsmit et al.
(43) based on a deterministic model.
How much bigger is the global effective population size than
the within-patient effective size? The ratio of nucleotide
diversity estimates obtained within and between patients
should reflect the ratio of the effective population size.
Difficulties arise in making these comparisons because of the
rapid saturation of synonymous substitutions, but estimates of
nucleotide diversity for the V3 region between independent
subtype B isolates lie between two and four times the value
observed within many patients (44). This argument suggests
that the subtype B effective population size would not be much
greater than 104, reflecting the short time since the epidemic
in the United States originated and probably a high variance
in the number of transmissions from each infected patient. In
a discussion based on analysis of the structure of their phylo-
genetic trees, Nee et al. (45) also have concluded that the global
populations of both HIV and hepatitis C virus are a long way
from evolutionary equilibrium. The effective population size
for other viruses may therefore also be low.
†Harrigan, R., Bloor, S. & Larder, B., Fifth International Workshop
on HIV Drug Resistance, July 3–5, 1996, Whistler, British Columbia,
Canada.
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